May 29, 2024 06:48 GMT
Merck (MRK: A1 pos / A+): Acquisition
HEALTHCARE
WSJ reports that Merck is close to entering the eye-care market with a $1.3bn (+$1.7bn potential add-ons) deal to buy Eyebiotech.
- Merck's Keytruda makes up 40% of sales and loses patent protection in 2028.
- Merck have recently acquiredPrometheus for $10.8b and Acceleron for $11.5b
44 words